首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1517630

去氧肾上腺素药物市场 - 副产品（片剂、糖浆、眼药水）、给药途径（口服、肠胃外）、适应症（感冒、鼻减充血、过敏反应）、配销通路（医院、零售和在线） - 2024 年全球预测 - 2032

Phenylephrine Drugs Market - By Product (Tablets, Syrup, Eye Drops), Route of Administration (Oral, Parenteral), Indication (Cold, Nasal Decongestion, Allergic Reaction), Distribution Channel (Hospital, Retail, & Online) - Global Forecast 2024 - 2032

出版日期: 2024年04月23日 | 出版商:

Global Market Insights Inc. | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于全球过敏性鼻炎、感冒和鼻窦炎盛行率不断上升，预计去氧肾上腺素药物市场规模在 2024 年至 2032 年间将以 6.6% 的复合年增长率增长。根据世界过敏组织的数据，过敏性鼻炎影响超过 4 亿人，成人盛行率在 10% 至 30% 之间，儿童盛行率超过 40%。由于城市化、污染和气候变迁等因素，这些情况变得更加普遍，对有效减充血剂的需求不断增加。

去氧肾上腺素因其缓解鼻腔和鼻窦充血的功效而被广泛用于非处方药 (OTC)，使其成为製药行业的主要产品。寻求立即缓解充血症状的消费者也更喜欢这些药物，因为它们起效迅速且无需处方即可获得。製药公司正在投资研发活动，以提高去氧肾上腺素产品的功效、安全性和患者依从性。这包括创建缓释製剂、与其他活性成分的联合疗法以及新颖的递送系统，例如鼻喷剂和吸入器。卫生当局的监管批准和认可确保去氧肾上腺素仍然是值得信赖和广泛使用的药物，进一步刺激市场成长。

本产业分为产品类型、给药途径、适应症、配销通路和地区。

根据产品类型，糖浆领域的去氧肾上腺素药物市场价值预计在 2024 年至 2032 年期间将大幅复合年增长率。这一增长得益于消费者和医疗保健提供者对治疗充血的广泛接受和偏好，特别是在儿科和老年人群中。糖浆剂提供了一种可口且易于服用的片剂和胶囊替代品，使其成为吞嚥药片有困难的儿童和老年患者的理想选择。液体形式还可以实现精确剂量，这对于敏感人群的安全有效治疗至关重要。

就适应症而言，预计到 2032 年，过敏反应领域的去氧肾上腺素药物产业将录得可观的成长率。随着越来越多的人经历季节性过敏、过敏性鼻炎和其他过敏性疾病，对可靠的减充血剂来快速缓解的需求不断增加。其可及性和有效性也使得基于去氧肾上腺素的产品在治疗过敏症状方面很受欢迎，从而推动了细分市场的成长。

亚太地区去氧肾上腺素药物产业预计在预测期内呈现显着的复合年增长率。这是由于城市化进程的不断加速和相关污染水平的提高，导致呼吸道和过敏性疾病的发生率更高。中国、印度和日本等国家製药业的强劲成长促进了去氧肾上腺素药物的广泛供应和生产。政府改善医疗基础设施的措施和自我药疗的上升趋势将进一步促进区域市场的成长。

产业生态系统分析
产业影响力
- 成长动力
  - 呼吸道疾病发生率上升
  - 药物输送系统的进展
  - 越来越多地转向非镇静减充血剂
  - 医疗保健支出不断增长
- 产业陷阱与挑战
  - 与伪麻黄碱相比功效有限
  - 轻鬆取得替代药物
成长潜力分析
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪錶板

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

主要趋势
平板电脑
糖浆
眼药水
其他产品类型

第 6 章：市场估计与预测：按管理途径，2018 年 - 2032 年

主要趋势
口服
注射用
其他给药途径

第 7 章：市场估计与预测：按指标划分，2018 年 - 2032 年

主要趋势
寒冷的
鼻腔减充血
过敏反应
眼部疾病
其他适应症

第 8 章：市场估计与预测：按配销通路，2018 年 - 2032 年

主要趋势
医院药房
药局和零售药局
网路药局

第 9 章：市场估计与预测：按地区划分，2018 年 - 2032 年

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Novartis AG
Perrigo Company PLC
Johnson & Johnson Consumer Inc. (Kenvue Inc.)
Proctor & Gamble Co.
Pfizer, Inc.
Foundation Consumer Brands LLC
Mylan N.V.
Torrent Pharmaceuticals, Inc.
GlaxoSmithKline PLC
Bayer AG

简介目录

Product Code: 9161

Phenylephrine drugs market size is anticipated to register 6.6% CAGR between 2024 and 2032, driven by the increasing prevalence of allergic rhinitis, colds, and sinusitis worldwide. As per World Allergy Organization, allergic rhinitis affects over 400 million individuals, with prevalence rates ranging from 10% to 30% among adults and exceeding 40% among children. As these conditions become more common due to factors, such as urbanization, pollution, and changing climates, the demand for effective decongestants is rising.

Phenylephrine is widely used in over the counter (OTC) medications for its efficacy in relieving nasal and sinus congestion, making it a staple in the pharmaceutical industry. Consumers seeking immediate relief from congestion symptoms also prefer these drugs due to their rapid action and availability without prescription. Pharmaceutical companies are investing in R&D activities to enhance the efficacy, safety, and patient compliance of phenylephrine products. This includes the creation of sustained-release formulations, combination therapies with other active ingredients, and novel delivery systems, such as nasal sprays and inhalers. Regulatory approvals and endorsements by health authorities are ensuring that phenylephrine remains a trusted and widely used drug, further stimulating the market growth.

The industry is classified into product type, route of administration, indication, distribution channel, and region.

Based on product type, the phenylephrine drugs market value from the syrup segment is slated to witness substantial CAGR during 2024-2032. The growth is favored by the widespread acceptance and preference among both consumers and healthcare providers for treating congestion, particularly in pediatric and geriatric populations. Syrups offer a palatable and easy-to-administer alternative to tablets and capsules, making them ideal for children and elderly patients who may have difficulty swallowing pills. The liquid form also allows precise dosing, which is crucial for safe and effective treatment in sensitive groups.

In terms of indication, the phenylephrine drugs industry from the allergic reaction segment is predicted to record decent growth rate through 2032. This is influenced by the rising prevalence of allergies and related symptoms, such as nasal congestion and sinus pressure. As more individuals experience seasonal allergies, allergic rhinitis, and other allergic conditions, there is an increasing demand for reliable decongestants to provide quick relief. The accessibility and effectiveness also makes phenylephrine-based products popular for managing allergy symptoms, driving segment growth.

Asia Pacific phenylephrine drugs industry is poised to depict notable CAGR over the forecast period. This is attributed to the increasing urbanization and associated pollution levels, which contribute to higher incidences of respiratory and allergic conditions. The robust growth of the pharmaceutical industry in countries, such as China, India, and Japan are facilitating the widespread availability and production of phenylephrine drugs. Government initiatives to improve healthcare infrastructure and the rising trend of self-medication will further bolster the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of respiratory diseases
  - 3.2.1.2 Advancement in drug delivery system
  - 3.2.1.3 Increase in shift towards non-sedating decongestants
  - 3.2.1.4 Growing healthcare expenditure
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited efficacy compared to pseudoephedrine
  - 3.2.2.2 Easy availability of alternative drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Million)

5.1 Key trends
5.2 Tablets
5.3 Syrups
5.4 Eye drops
5.5 Other product types

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Million)

6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Indication, 2018 - 2032 ($ Million)

7.1 Key trends
7.2 Cold
7.3 Nasal decongestion
7.4 Allergic reaction
7.5 Eye disease
7.6 Other indications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Million)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug stores & retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa